$AMLX News

Mizuho Maintains Outperform on Amylyx Pharmaceuticals, Raises Price Target to $42

Guggenheim Maintains Buy on Amylyx Pharmaceuticals, Raises Price Target to $55

Baird Maintains Outperform on Amylyx Pharmaceuticals, Raises Price Target to $52

HC Wainwright & Co. Maintains Buy on Amylyx Pharmaceuticals, Raises Price Target to $55

Amylyx Pharmaceuticals, Inc. (AMLX) Discusses Positive Phase III LUCIDITY Topline Results for Avexitide in Post-Bariatric Hypoglycemia Transcript

Amylyx: Upgraded To Strong Buy On LUCIDITY Outcome, Avexitide, And 2026 Catalysts

Amylyx Pharmaceuticals, Inc. (AMLX) Discusses Positive Phase III LUCIDITY Topline Results for Avexitide in Post-Bariatric Hypoglycemia - Slideshow

Amylyx Pharmaceuticals Comes Closer to Potentially Delivering First Treatment for Weight Loss Surgery-Related Low Suger Level

Amylyx Pharmaceuticals Says LUCIDITY Phase 3 Trial Met Its Primary Endpoint, Demonstrating 55% Reduction in Level 2 and Level 3 Hypoglycemic Events Vs. Placebo

Amylyx Pharmaceuticals Stock Soars After the Close: Here's Why

Amylyx Pharmaceuticals To Announce Phase 3 LUCIDITY Trial Topline Results For Avexitide In Post-Bariatric Hypoglycemia On August 18 At 8:00 a.m. ET

Mizuho Maintains Outperform on Amylyx Pharmaceuticals, Raises Price Target to $30

Amylyx Pharmaceuticals: Avexitide Defines The Endocrine Rebuild

Amylyx Pharmaceuticals, Inc. (AMLX) Q2 2026 Earnings Call Transcript

Amylyx Pharmaceuticals (NASDAQ:AMLX) Misses on Q2 Bottom Line as LUCIDITY Readout Looms

RAmylyx Pharma Q2 EPS $(0.39) Misses $(0.36) Estimate, Cash & Equivalents $279.8M. Cash runway Expected To Fund Operations Till 2028

Citigroup Maintains Buy on Amylyx Pharmaceuticals, Raises Price Target to $26

Mizuho Maintains Outperform on Amylyx Pharmaceuticals, Raises Price Target to $24

Guggenheim Maintains Buy on Amylyx Pharmaceuticals, Raises Price Target to $40

Amylyx Pharma To Present Data From First-In-Human, Dose-Ranging Phase 1 LUMINA Trial Of AMX0114 At ENCALS Meeting 2026